Desenvolupament i recerca de medicaments contra la Covid-19 (Catalan Wikipedia)

Analysis of information sources in references of the Wikipedia article "Desenvolupament i recerca de medicaments contra la Covid-19" in Catalan language version.

refsWebsite

Global rank Catalan rank

53nih.gov

4^th place

7^th place

51doi.org

2^nd place

6^th place

22worldcat.org

5^th place

5nature.com

234^th place

127^th place

4fda.gov

447^th place

656^th place

4thelancet.com

2,393^rd place

2,029^th place

4reuters.com

49^th place

152^nd place

3web.archive.org

1^st place

3jci.org

low place

2europa.eu

68^th place

49^th place

2jst.go.jp

1,903^rd place

2,300^th place

2nejm.org

2,374^th place

2,440^th place

2theguardian.com

12^th place

35^th place

2oup.com

485^th place

330^th place

1bioworld.com

low place

1biorender.com

low place

1sciencemag.org

857^th place

278^th place

1clinicaltrialsarena.com

low place

1bloomberg.com

99^th place

435^th place

1statnews.com

8,771^st place

low place

1scmp.com

362^nd place

1,588^th place

1cmaj.ca

low place

5,807^th place

1airtable.com

low place

1milkeninstitute.org

low place

1biocentury.com

low place

1bmj.com

1,226^th place

517^th place

1ft.com

210^th place

493^rd place

1publico.es

1,892^nd place

105^th place

1independent.co.uk

36^th place

129^th place

1technologyreview.com

1,943^rd place

2,446^th place

1ilfattoquotidiano.it

823^rd place

3,794^th place

1aifa.gov.it

low place

1rdif.ru

low place

1bnnbloomberg.ca

low place

1indiatoday.in

94^th place

6,240^th place

1pfizer.com

low place

1cdc.gov

218^th place

281^st place

1infoanoia.cat

low place

2,568^th place

1drugbank.ca

4,294^th place

low place

1uniprot.org

5,673^rd place

1,299^th place

1airicerca.org

low place

1sciencedirect.com

149^th place

111^th place

1monash.edu

low place

1eurjrheumatol.org

low place

1theconversation.com

928^th place

1,431^st place

1elsevier.com

610^th place

253^rd place

1who.int

195^th place

155^th place

1nytimes.com

7^th place

14^th place

1aemps.gob.es

low place

932^nd place

1recoverytrial.net

low place

1rimed.org

low place

1chinaxiv.org

low place

1ansa.it

493^rd place

1,829^th place

1biomedcentral.com

2,747^th place

771^st place

1drugbank.com

low place

8,838^th place

1jhu.edu

699^th place

1,067^th place

1acs.org

1,248^th place

405^th place

1bbc.com

20^th place

66^th place

1exeter.ac.uk

6,124^th place

low place

acs.org

cen.acs.org

Howell, L. «Structure of novel coronavirus spike protein solved in just weeks». Chemical & Engineering News, 2020; Feb 19. [Consulta: 10 novembre 2020].

aemps.gob.es

AEMPS «La AEMPS toma medidas con respecto a los ensayos clínicos para la COVID-19 con hidroxicloroquina» (en castellà). Acciones informativas, 2020; Juny 22, MUH 15/2020, pàgs: 2 [Consulta: 23 juny 2020].

aifa.gov.it

«AIFA precisa, uso favipiravir per COVID-19 non autorizzato in Europa e USA, scarse evidenze scientifiche sull'efficacia» (en italià). [Consulta: 23 març 2020].

airicerca.org

informa.airicerca.org

Multicenter collaboration group of Department of Science Technology of Guangdong Province Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia «Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia» (en xinés). Chinese Journal of Tuberculosis and Respiratory Diseases (Zhonghua Jie He He Hu Xi Za Zhi), 43, febrer 2020, pàg. E019. DOI: 10.3760/cma.j.issn.1001-0939.2020.0019. PMID: 32075365.

airtable.com

«COVID-19 vaccine and treatments tracker (Choose vaccines or treatments tab, apply filters to view select data)». Milken Institute, 14-01-2021. [Consulta: 18 gener 2021].

ansa.it

Redacció. «3 patients get better on arthritis drug» (en anglès). ANSA, 05-03-2020. [Consulta: 14 març 2020].

bbc.com

Gallagher, J. «BCG: Can a vaccine from 1921 save lives from Covid-19?» (en anglès). Health, BBC News, 11-10-2020.

biocentury.com

Koch, Selina; Pong, Winnie. «First up for COVID-19: nearly 30 clinical readouts before end of April». BioCentury Inc., 13-03-2020. [Consulta: 1r abril 2020].

biomedcentral.com

ccforum.biomedcentral.com

Stallmach, A; Kortgen, A; Gonnert, F; Coldewey, SM; et al «Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series». Crit Care, 2020 Jul 17; 24 (1), pp: 444. DOI: 10.1186/s13054-020-03158-0. ISSN: 1466-609X. PMID: 32680535 [Consulta: 21 juliol 2020].

biorender.com

«COVID-19 vaccine and therapeutics tracker». BioRender, 15-01-2021. [Consulta: 18 gener 2021].

bioworld.com

«Biopharma products in development for COVID-19». BioWorld, 02-11-2020. [Consulta: 3 novembre 2020].

bloomberg.com

«Chinese Vaccine Approved for Human Testing at Virus Epicenter». Bloomberg News, 19-03-2020 [Consulta: 21 març 2020].

bmj.com

bestpractice.bmj.com

Beeching, Nicholas J.; Fletcher, Tom E.; Fowler, Robert «BMJ Best Practices: COVID-19». BMJ, 2020; Abr 14 (rev), pàgs: 111. Arxivat de l'original el 19 de desembre 2020 [Consulta: 20 desembre 2020].

bnnbloomberg.ca

«Russian Health Ministry approves anti-coronavirus drug Avifavir». BNN Bloomberg, 31-05-2020 [Consulta: 31 maig 2020].

cdc.gov

«Coronavirus Disease 2019 (COVID-19)» (en anglès). Centers for Disease Control and Prevention, 11-02-2020. [Consulta: 11 març 2020].

chinaxiv.org

«Effective Treatment of Severe COVID-19 Patients with Tocilizumab». ChinaXiv.org, 05-03-2020. DOI: 10.12074/202003.00026. [Consulta: 14 març 2020].

clinicaltrialsarena.com

«China approves first anti-viral drug against coronavirus Covid-19». Clinical Trials Arena, 18-02-2020. [Consulta: 21 març 2020].

cmaj.ca

«Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic». Canadian Medical Association Journal, 192, 15, 26-03-2020, pàg. E405–E407. DOI: 10.1503/cmaj.200438. ISSN: 0820-3946. PMC: 7162442. PMID: 32336678 [Consulta: 27 març 2020].

doi.org

dx.doi.org

Kupferschmidt, Kai; Cohen, Jon «WHO launches global megatrial of the four most promising coronavirus treatments». Science Magazine, 22-03-2020. DOI: 10.1126/science.abb8497 [Consulta: 27 març 2020].
«COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics». Human Vaccines & Immunotherapeutics, 16, 6, març 2020, pàg. 1232–1238. DOI: 10.1080/21645515.2020.1735227. PMC: 7103671. PMID: 32186952.
«Potential interventions for novel coronavirus in China: A systematic review». Journal of Medical Virology, 92, 5, maig 2020, pàg. 479–490. DOI: 10.1002/jmv.25707. PMC: 7166986. PMID: 32052466.
COVID-19 Clinical Research Coalition «Global coalition to accelerate COVID-19 clinical research in resource-limited settings». Lancet, 395, 10233, abril 2020, pàg. 1322–1325. DOI: 10.1016/s0140-6736(20)30798-4. PMC: 7270833. PMID: 32247324.
Maguire, Brittany J.; Guérin, Philippe J. «A living systematic review protocol for COVID-19 clinical trial registrations». Wellcome Open Research, 5, 02-04-2020, pàg. 60. DOI: 10.12688/wellcomeopenres.15821.1. ISSN: 2398-502X. PMC: 7141164. PMID: 32292826.
«Therapeutic options for the 2019 novel coronavirus (2019-nCoV)». Nature Reviews. Drug Discovery, 19, 3, març 2020, pàg. 149–150. DOI: 10.1038/d41573-020-00016-0. PMID: 32127666.
«Therapeutic options for the 2019 novel coronavirus (2019-nCoV)». Nature Reviews. Drug Discovery, 19, 3, març 2020, pàg. 149–150. DOI: 10.1038/d41573-020-00016-0. PMID: 32127666.
«Discovering drugs to treat coronavirus disease 2019 (COVID-19)». Drug Discoveries & Therapeutics, 14, 1, 29-02-2020, pàg. 58–60. DOI: 10.5582/ddt.2020.01012. PMID: 32147628.
«Coronavirus puts drug repurposing on the fast track». Nature Biotechnology, 38, 4, febrer 2020, pàg. 379–381. DOI: 10.1038/d41587-020-00003-1. PMID: 32205870.
«Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic». Canadian Medical Association Journal, 192, 15, 26-03-2020, pàg. E405–E407. DOI: 10.1503/cmaj.200438. ISSN: 0820-3946. PMC: 7162442. PMID: 32336678 [Consulta: 27 març 2020].
Shaffer, L «15 drugs being tested to treat COVID-19 and how they would work» (en anglès). Nat Med, 2020; Maig 15, pàgs: 8. ISSN 1546-170X. DOI: 10.1038/d41591-020-00019-9. PMID: 32415251 [Consulta: 19 maig 2020].
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G; 6 «Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro». Cell Research, 30, 3, febrer 2020, pp: 269–271. DOI: 10.1038/s41422-020-0282-0. PMC: 7054408. PMID: 32020029.
Li G, De Clercq E «Therapeutic options for the 2019 novel coronavirus (2019-nCoV)». Nature Reviews. Drug Discovery, 19, 3, març 2020, pàg. 149–150. ISSN 1474-1784. DOI: 10.1038/d41573-020-00016-0. PMID: 32127666.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T; 8 «Compassionate Use of Remdesivir for Patients with Severe Covid-19». N Engl J Med, 2020 Abr; 10, pàgs: 19. ISSN 1533-4406. DOI: 10.1056/NEJMoa2007016. PMID: 32275812.
Beigel, JH; Tomashek, KM; Dodd, LE; Mehta, AK; et al «Remdesivir for the Treatment of Covid-19 - Preliminary Report» (en anglès). N Engl J Med, 2020; Maig 22, pp: NEJMoa2007764. PMID: 32445440. DOI: 10.1056/NEJMoa2007764. PMC: 7262788 [Consulta: 3 juliol 2020].
Gregoire, M; Le Turnier, P; Gaborit, BJ; Veyrac, G; et al «Lopinavir pharmacokinetics in COVID-19 patients» (en anglès). J Antimicrob Chemother, 2020; Maig 22, pp: dkaa195. ISSN 1460-2091. DOI: 10.1093/jac/dkaa195. PMID: 32443151 [Consulta: 23 maig 2020].
Cao B, Wang Y, Wen D, Liu W, et al «A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19». The New England Journal of Medicine, 382, 19, 07-05-2020, pp: 1787–1799. DOI: 10.1056/NEJMoa2001282. PMC: 7121492. PMID: 32187464.
Meini, S; Pagotto, A; Longo, B; Vendramin, I; et al «Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives» (en anglès). J Clin Med, 2020 Jun 30; 9 (7), pp: 2050. PMID: 32629768. DOI: 10.3390/jcm9072050. PMC: 7408758 [Consulta: 26 setembre 2020].
Kim, EJ; Choi, SH; Park, SJ; Kwon, YS; et al «Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection» (en anglès). Yonsei Med J, 2020 Set; 61 (9), pp: 826-830. PMID: 32882767. DOI: 10.3349/ymj.2020.61.9.826. PMC: 7471078 [Consulta: 27 setembre 2020].
Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, et al «TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection» (en anglès). J Virol, 2020 Mar 5; 93 (6), pii: e01815-18. PMID: 30626688. DOI: 10.1128/JVI.01815-18. PMC: 6401451 [Consulta: 6 abril 2020].
Gao J, Tian Z, Yang X «Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies» (en anglès). Bioscience Trends, 14, 1, 19-02-2020, pp: 72–73. DOI: 10.5582/bst.2020.01047. ISSN: 1881-7823. PMID: 32074550.
Touret F, de Lamballerie X «/ Of chloroquine and COVID-19» (en anglès). Antiviral Research, 2020 Mar 15; 177, pp: 104762. PMID: 32147496. DOI: 10.1016/j.antiviral.2020.104762. PMC: 7132364 [Consulta: 19 abril 2020].
Multicenter collaboration group of Department of Science Technology of Guangdong Province Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia «Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia» (en xinés). Chinese Journal of Tuberculosis and Respiratory Diseases (Zhonghua Jie He He Hu Xi Za Zhi), 43, febrer 2020, pàg. E019. DOI: 10.3760/cma.j.issn.1001-0939.2020.0019. PMID: 32075365.
Self, Wesley H.; Semler, Matthew W.; Leither, Lindsay M.; Casey, Jonathan D.; Angus, Derek C.; Brower, Roy G.; Chang, Steven Y.; Collins, Sean P.; Eppensteiner, John C. «Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19». JAMA, 324, 21, novembre 2020, pàg. 2165–2176. DOI: 10.1001/jama.2020.22240. PMC: 7653542. PMID: 33165621.
Miossec, P «Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation» (en anglès). Eur J Rheumatol, 2020; Maig 11, pàgs: 2. ISSN 2148-4279. DOI: 10.5152/eurjrheum.2020.2062. PMID: 32412405 [Consulta: 18 maig 2020].^{[Enllaç no actiu]}
Touret, F; de Lamballerie, X «Of chloroquine and COVID-19» (en anglès). Antiviral Res, 2020 Maig; 177, pp: 104762. PMID: 32147496. DOI: 10.1016/j.antiviral.2020.104762. PMC: 7132364 [Consulta: 6 setembre 2020].
Molina, Jean Michel; Delaugerre, Constance; Goff, Jerome Le; Mela-Lima, Breno; Ponscarme, Diane; Goldwirt, Lauriane; de Castro, Nathalie «No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection» (en frànces). Médecine et Maladies Infectieuses, 2020-03, pp: S0399077X20300858. DOI: 10.1016/j.medmal.2020.03.006.
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D; 8 «In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)». Clinical Infectious Diseases, 2020; Mar 9, pp: ciaa237. DOI: 10.1093/cid/ciaa237. PMC: 7108130. PMID: 32150618.
Mehra, Mandeep R.; Desai, Sapan S.; Ruschitzka, Frank; Patel, Amit N. «Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis» (en anglès). The Lancet (Epub AoP), 22-05-2020. DOI: 10.1016/S0140-6736(20)31180-6. ISSN: 0140-6736. PMID: 32450107.
Editors «Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis» (en anglès). The Lancet, 2020; Jun 3, pàgs: 1. DOI: 10.1016/S0140-6736(20)31290-3 [Consulta: 4 juny 2020].
Mitjà, Oriol; Corbacho-Monné, Marc; Ubals, Maria; Tebe, Cristian; Peñafiel, Judith «Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial». Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 16-07-2020. DOI: 10.1093/cid/ciaa1009. ISSN: 1537-6591. PMC: 7454406. PMID: 32674126.
Andreakos E, Tsiodras S «COVID-19: lambda interferon against viral load and hyperinflammation» (en anglès). EMBO Mol Med, 2020; Maig 25, pp: e12465. ISSN 1757-4684. DOI: 10.15252/emmm.202012465. PMID: 32333818 [Consulta: 9 juny 2020].
Mantlo, E; Bukreyeva, N; Maruyama, J; Paessler, S; Huang, C «Antiviral activities of type I interferons to SARS-CoV-2 infection» (en anglès). Antiviral Res, 2020 Jul; 179, pp: 104811. PMID: 32360182. DOI: 10.1016/j.antiviral.2020.104811. PMC: 7188648 [Consulta: 26 juny 2020].
Yang, JW; Yang, L; Luo, RG; Xu, JF «Successful use of methylprednisolone for treating severe COVID-19» (en anglès). Clin Microbiol Infect, 2020; Maig 29 (Epub Aop), pàgs: 5. PMID: 32479759. DOI: 10.1016/j.jaci.2020.05.021. PMC: 7256545 [Consulta: 3 juliol 2020].
Konig MF, Powell MA, Staedtke V, Bai RY, et al «Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists» (en anglès). J Clin Invest, 2020; Maig 26, pii: 139642. ISSN 1558-8238. DOI: 10.1172/JCI139642. PMID: 32352407 [Consulta: 26 juny 2020].
«Effective Treatment of Severe COVID-19 Patients with Tocilizumab». ChinaXiv.org, 05-03-2020. DOI: 10.12074/202003.00026. [Consulta: 14 març 2020].
Rodríguez-Baño, J; Pachón, J; Carratalà, J; Ryan, P; et al «Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)». Clin Microbiol Infect, 2020; Ag 26, pp: S1198-743X(20)30492-4. DOI: 10.1016/j.cmi.2020.08.010. PMC: 7449935. PMID: 32860964 [Consulta: 1r setembre 2020].
Mehta, P; Porter, JC; Manson, JJ; Isaacs, JD; Openshaw, PJM; McInnes, IB; Summers, C; Chambers, RC «Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities». Lancet Respir Med, 16-06-2020, pp: S2213-2600(20)30267-8. DOI: 10.1016/S2213-2600(20)30267-8. ISSN: 2213-2619. PMID: 32559419 [Consulta: 25 juny 2020].
Stallmach, A; Kortgen, A; Gonnert, F; Coldewey, SM; et al «Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series». Crit Care, 2020 Jul 17; 24 (1), pp: 444. DOI: 10.1186/s13054-020-03158-0. ISSN: 1466-609X. PMID: 32680535 [Consulta: 21 juliol 2020].
Cavalli, G; De Luca, G; Campochiaro, C; Della-Torre, E; et al «Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study». Lancet Rheumatol, 2020 Jun; 2 (6), pp: e325-e331. DOI: 10.1016/S2665-9913(20)30127-2. PMC: 7252085. PMID: 32501454 [Consulta: 1r setembre 2020].
Huet, T; Beaussier, H; Voisin, O; Jouveshomme, S; et al «Anakinra for severe forms of COVID-19: a cohort study». Lancet Rheumatol, 2020 Jul; 2 (7), pp: e393-e400. DOI: 10.1016/S2665-9913(20)30164-8. PMC: 7259909. PMID: 32835245 [Consulta: 1r setembre 2020].
Chen, P; Nirula, A; Heller, B; Gottlieb, RL; et al «SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19» (en anglès). , 2020; Oct 28, pàgs: 18. PMID: 33113295. DOI: 10.1056/NEJMoa2029849. ISSN: 1533-4406 [Consulta: 10 novembre 2020].
Casadevall A, Pirofski LA «The convalescent sera option for containing COVID-19». The Journal of Clinical Investigation, 130, 4, 13-03-2020, pp: 1545–1548. DOI: 10.1172/JCI138003. PMC: 7108922. PMID: 32167489.
Piechotta, Vanessa; Chai, Khai Li; Valk, Sarah J.; Doree, Carolyn; Monsef, Ina; Wood, Erica M.; Lamikanra, Abigail; Kimber, Catherine; McQuilten, Zoe; So-Osman, Cynthia; Estcourt, Lise J. «Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review». The Cochrane Database of Systematic Reviews, 7, 10-07-2020, pàg. CD013600. DOI: 10.1002/14651858.CD013600.pub2. ISSN: 1469-493X. PMID: 32648959.
AminJafari, A; Ghasemi, S «The possible of immunotherapy for COVID-19: A systematic review» (en anglès). Int Immunopharmacol, 2020 Jun; 83, pp: 106455. PMID: 32272396. DOI: 10.1016/j.intimp.2020.106455. PMC: 7128194 [Consulta: 15 juliol 2020].
Montelongo-Jauregui, D; Vila, T; Sultan, AS; Jabra-Rizk, MA «Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease» (en anglès). PLoS Pathog, 2020 Ag 12; 16 (8), pp: e1008735. PMID: 32785259. DOI: 10.1371/journal.ppat.1008735. PMC: 7423094 [Consulta: 15 desembre 2020].
Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M «COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19» (en anglès). Antibody Therapeutics, 2020 Ag 19; 3 (3), pp: 204–211. DOI: 10.1093/abt/tbaa020. ISSN: 2516-4236. PMC: 7454247.
Mohapatra, Prasanta Raghab; Mishra, Baijayantimala; Behera, Bijayini «BCG vaccination induced protection from COVID-19» (en anglès). The Indian Journal of Tuberculosis, 07-08-2020, pàgs: 11. ISSN 0019-5707. DOI: 10.1016/j.ijtb.2020.08.004. PMC: 7413058.
Curtis, N; Sparrow, A; Ghebreyesus, TA; Netea, MG «Considering BCG vaccination to reduce the impact of COVID-19» (en anglès). Lancet, 2020 Maig 16; 395 (10236), pp: 1545-1546. DOI: 10.1016/S0140-6736(20)31025-4. PMC: 7252177. PMID: 32359402 [Consulta: 11 novembre 2020].
Noval Rivas, M; Ebinger, JE; Wu, M; Sun, N; et al «BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers» (en anglès). J Clin Invest, 2020; Nov 19, pp: 145157. DOI: 10.1172/JCI145157. ISSN: 1558-8238. PMID: 33211672 [Consulta: 20 desembre 2020].
Takahashi, Harutaka «Role of latent tuberculosis infections in reduced COVID-19 mortality: Evidence from an instrumental variable method analysis» (en anglès). Medical Hypotheses, 144, 04-11-2020, pp: 110214. ISSN 0306-9877. DOI: 10.1016/j.mehy.2020.110214. PMC: 7448767.

drugbank.ca

DrugBank «Camostat» (en anglès). Canadian Institutes of Health Research/The Metabolomics Innovation Centre, 2020 Abr 5; DB13729 (rev), pàgs: 6 [Consulta: 6 abril 2020].

drugbank.com

go.drugbank.com

DrugBank «Bamlanivimab» (en anglès). Canadian Institutes of Health Research/The Metabolomics Innovation Centre, 2020 Oct 12; DB15718 (rev), pàgs: 3 [Consulta: 10 novembre 2020].

elsevier.com

linkinghub.elsevier.com

Molina, Jean Michel; Delaugerre, Constance; Goff, Jerome Le; Mela-Lima, Breno; Ponscarme, Diane; Goldwirt, Lauriane; de Castro, Nathalie «No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection» (en frànces). Médecine et Maladies Infectieuses, 2020-03, pp: S0399077X20300858. DOI: 10.1016/j.medmal.2020.03.006.

eurjrheumatol.org

Miossec, P «Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation» (en anglès). Eur J Rheumatol, 2020; Maig 11, pàgs: 2. ISSN 2148-4279. DOI: 10.5152/eurjrheum.2020.2062. PMID: 32412405 [Consulta: 18 maig 2020].^{[Enllaç no actiu]}

europa.eu

ema.europa.eu

«First regulatory workshop on COVID-19 facilitates global collaboration on vaccine development». European Medicines Agency, 18-03-2020. [Consulta: 21 març 2020].
«Call to pool research resources into large multi-centre, multi-arm clinical trials to generate sound evidence on COVID-19 treatments». European Medicines Agency, 19-03-2020. [Consulta: 21 març 2020].

exeter.ac.uk

medicine.exeter.ac.uk

Primary Care Team. «BCG vaccination to reduce the impact of COVID-19 in healthcare workers (The BRACE Trial)» (en anglès). College of Medicine and Health, University of Exeter, 12-10-2020.

fda.gov

U.S. Food and Drug Administration (FDA) (19 març 2020). "Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments". Nota de premsa.
«The Drug Development Process». U.S. Food and Drug Administration (FDA), 04-01-2018. [Consulta: 21 març 2020].
(21 novembre 2020). "Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19". Nota de premsa. Aquest article incorpora text d'aquesta font, la qual és de domini públic.
U.S. Food and Drug Administration (FDA) «Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19» (en anglès). Press Announcements, 09-11-2020 [Consulta: 11 novembre 2020].

ft.com

Mancini, DP; Kuchler, H «Gilead antiviral drug remdesivir flops in first trial» (en anglès). Financial Times, 2020; Abr 23, págs: 3 [Consulta: 24 abril 2020].

ilfattoquotidiano.it

«Coronavirus, il Veneto sperimenta l'antivirale giapponese Favipiravir. Ma l'Aifa: "Ci sono scarse evidenze scientifiche su efficacia"» (en italià), 22-03-2020. [Consulta: 23 març 2020].

independent.co.uk

«Coronavirus: Japanese anti-viral drug effective in treating patients, Chinese official says». The Independent.

indiatoday.in

«Glenmark's FabiFlu approved for coronavirus treatment in India, costs Rs 103 per tablet» (en anglès). India Today, 20-06-2020 [Consulta: 30 juny 2020].

infoanoia.cat

Redacció. «L'assaig clínic pel coronavirus es farà a Igualada i al nord de l'àrea metropolitana de Barcelona». Infoanoia, 16-03-2020. [Consulta: 16 març 2020].

jci.org

Konig MF, Powell MA, Staedtke V, Bai RY, et al «Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists» (en anglès). J Clin Invest, 2020; Maig 26, pii: 139642. ISSN 1558-8238. DOI: 10.1172/JCI139642. PMID: 32352407 [Consulta: 26 juny 2020].
Casadevall A, Pirofski LA «The convalescent sera option for containing COVID-19». The Journal of Clinical Investigation, 130, 4, 13-03-2020, pp: 1545–1548. DOI: 10.1172/JCI138003. PMC: 7108922. PMID: 32167489.
Noval Rivas, M; Ebinger, JE; Wu, M; Sun, N; et al «BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers» (en anglès). J Clin Invest, 2020; Nov 19, pp: 145157. DOI: 10.1172/JCI145157. ISSN: 1558-8238. PMID: 33211672 [Consulta: 20 desembre 2020].

jhu.edu

hub.jhu.edu

Pearce, Katie. «Antibodies from COVID-19 survivors could be used to treat patients, protect those at risk: Infusions of antibody-laden blood have been used with reported success in prior outbreaks, including the SARS epidemic and the 1918 flu pandemic» (en anglès). The Hub at Johns Hopkins University, 13-03-2020. [Consulta: 14 març 2020].

jst.go.jp

jstage.jst.go.jp

«Discovering drugs to treat coronavirus disease 2019 (COVID-19)». Drug Discoveries & Therapeutics, 14, 1, 29-02-2020, pàg. 58–60. DOI: 10.5582/ddt.2020.01012. PMID: 32147628.
Gao J, Tian Z, Yang X «Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies» (en anglès). Bioscience Trends, 14, 1, 19-02-2020, pp: 72–73. DOI: 10.5582/bst.2020.01047. ISSN: 1881-7823. PMID: 32074550.

milkeninstitute.org

Milken Institute. «COVID-19 treatment and vaccine tracker», 02-04-2020. Arxivat de l'original el 27 de març 2020. [Consulta: 2 abril 2020].

monash.edu

Monash Biomedicine Discovery Institute. (n.d.). Possible coronavirus drug identified by Monash University scientists. [online] Available at: https://www.monash.edu/discovery-institute/news-and-events/news/2020-articles/possible-coronavirus-drug-identified-by-monash-university-scientists [Accessed 5 Apr. 2020].

nature.com

«Coronavirus puts drug repurposing on the fast track». Nature Biotechnology, 38, 4, febrer 2020, pàg. 379–381. DOI: 10.1038/d41587-020-00003-1. PMID: 32205870.
Shaffer, L «15 drugs being tested to treat COVID-19 and how they would work» (en anglès). Nat Med, 2020; Maig 15, pàgs: 8. ISSN 1546-170X. DOI: 10.1038/d41591-020-00019-9. PMID: 32415251 [Consulta: 19 maig 2020].
Li G, De Clercq E «Therapeutic options for the 2019 novel coronavirus (2019-nCoV)». Nature Reviews. Drug Discovery, 19, 3, març 2020, pàg. 149–150. ISSN 1474-1784. DOI: 10.1038/d41573-020-00016-0. PMID: 32127666.
Wang, C; Li, W; Drabek, D; Okba, NMA; et al «A human monoclonal antibody blocking SARS-CoV-2 infection» (en anglès). Nature Communications, 2020 Maig 4; 11 (2251), pàgs: 25. ISSN 2041-1723 [Consulta: 5 maig 2020].

media.nature.com

«Therapeutic options for the 2019 novel coronavirus (2019-nCoV)». Nature Reviews. Drug Discovery, 19, 3, març 2020, pàg. 149–150. DOI: 10.1038/d41573-020-00016-0. PMID: 32127666.

nejm.org

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T; 8 «Compassionate Use of Remdesivir for Patients with Severe Covid-19». N Engl J Med, 2020 Abr; 10, pàgs: 19. ISSN 1533-4406. DOI: 10.1056/NEJMoa2007016. PMID: 32275812.
Chen, P; Nirula, A; Heller, B; Gottlieb, RL; et al «SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19» (en anglès). , 2020; Oct 28, pàgs: 18. PMID: 33113295. DOI: 10.1056/NEJMoa2029849. ISSN: 1533-4406 [Consulta: 10 novembre 2020].

nih.gov

ncbi.nlm.nih.gov

«COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics». Human Vaccines & Immunotherapeutics, 16, 6, març 2020, pàg. 1232–1238. DOI: 10.1080/21645515.2020.1735227. PMC: 7103671. PMID: 32186952.
«Potential interventions for novel coronavirus in China: A systematic review». Journal of Medical Virology, 92, 5, maig 2020, pàg. 479–490. DOI: 10.1002/jmv.25707. PMC: 7166986. PMID: 32052466.
COVID-19 Clinical Research Coalition «Global coalition to accelerate COVID-19 clinical research in resource-limited settings». Lancet, 395, 10233, abril 2020, pàg. 1322–1325. DOI: 10.1016/s0140-6736(20)30798-4. PMC: 7270833. PMID: 32247324.
Maguire, Brittany J.; Guérin, Philippe J. «A living systematic review protocol for COVID-19 clinical trial registrations». Wellcome Open Research, 5, 02-04-2020, pàg. 60. DOI: 10.12688/wellcomeopenres.15821.1. ISSN: 2398-502X. PMC: 7141164. PMID: 32292826.
«Therapeutic options for the 2019 novel coronavirus (2019-nCoV)». Nature Reviews. Drug Discovery, 19, 3, març 2020, pàg. 149–150. DOI: 10.1038/d41573-020-00016-0. PMID: 32127666.
«Therapeutic options for the 2019 novel coronavirus (2019-nCoV)». Nature Reviews. Drug Discovery, 19, 3, març 2020, pàg. 149–150. DOI: 10.1038/d41573-020-00016-0. PMID: 32127666.
«Discovering drugs to treat coronavirus disease 2019 (COVID-19)». Drug Discoveries & Therapeutics, 14, 1, 29-02-2020, pàg. 58–60. DOI: 10.5582/ddt.2020.01012. PMID: 32147628.
«Coronavirus puts drug repurposing on the fast track». Nature Biotechnology, 38, 4, febrer 2020, pàg. 379–381. DOI: 10.1038/d41587-020-00003-1. PMID: 32205870.
«Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic». Canadian Medical Association Journal, 192, 15, 26-03-2020, pàg. E405–E407. DOI: 10.1503/cmaj.200438. ISSN: 0820-3946. PMC: 7162442. PMID: 32336678 [Consulta: 27 març 2020].
Shaffer, L «15 drugs being tested to treat COVID-19 and how they would work» (en anglès). Nat Med, 2020; Maig 15, pàgs: 8. ISSN 1546-170X. DOI: 10.1038/d41591-020-00019-9. PMID: 32415251 [Consulta: 19 maig 2020].
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G; 6 «Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro». Cell Research, 30, 3, febrer 2020, pp: 269–271. DOI: 10.1038/s41422-020-0282-0. PMC: 7054408. PMID: 32020029.
Li G, De Clercq E «Therapeutic options for the 2019 novel coronavirus (2019-nCoV)». Nature Reviews. Drug Discovery, 19, 3, març 2020, pàg. 149–150. ISSN 1474-1784. DOI: 10.1038/d41573-020-00016-0. PMID: 32127666.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T; 8 «Compassionate Use of Remdesivir for Patients with Severe Covid-19». N Engl J Med, 2020 Abr; 10, pàgs: 19. ISSN 1533-4406. DOI: 10.1056/NEJMoa2007016. PMID: 32275812.
Beigel, JH; Tomashek, KM; Dodd, LE; Mehta, AK; et al «Remdesivir for the Treatment of Covid-19 - Preliminary Report» (en anglès). N Engl J Med, 2020; Maig 22, pp: NEJMoa2007764. PMID: 32445440. DOI: 10.1056/NEJMoa2007764. PMC: 7262788 [Consulta: 3 juliol 2020].
Gregoire, M; Le Turnier, P; Gaborit, BJ; Veyrac, G; et al «Lopinavir pharmacokinetics in COVID-19 patients» (en anglès). J Antimicrob Chemother, 2020; Maig 22, pp: dkaa195. ISSN 1460-2091. DOI: 10.1093/jac/dkaa195. PMID: 32443151 [Consulta: 23 maig 2020].
Cao B, Wang Y, Wen D, Liu W, et al «A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19». The New England Journal of Medicine, 382, 19, 07-05-2020, pp: 1787–1799. DOI: 10.1056/NEJMoa2001282. PMC: 7121492. PMID: 32187464.
Meini, S; Pagotto, A; Longo, B; Vendramin, I; et al «Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives» (en anglès). J Clin Med, 2020 Jun 30; 9 (7), pp: 2050. PMID: 32629768. DOI: 10.3390/jcm9072050. PMC: 7408758 [Consulta: 26 setembre 2020].
Kim, EJ; Choi, SH; Park, SJ; Kwon, YS; et al «Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection» (en anglès). Yonsei Med J, 2020 Set; 61 (9), pp: 826-830. PMID: 32882767. DOI: 10.3349/ymj.2020.61.9.826. PMC: 7471078 [Consulta: 27 setembre 2020].
Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, et al «TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection» (en anglès). J Virol, 2020 Mar 5; 93 (6), pii: e01815-18. PMID: 30626688. DOI: 10.1128/JVI.01815-18. PMC: 6401451 [Consulta: 6 abril 2020].
Gao J, Tian Z, Yang X «Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies» (en anglès). Bioscience Trends, 14, 1, 19-02-2020, pp: 72–73. DOI: 10.5582/bst.2020.01047. ISSN: 1881-7823. PMID: 32074550.
Touret F, de Lamballerie X «/ Of chloroquine and COVID-19» (en anglès). Antiviral Research, 2020 Mar 15; 177, pp: 104762. PMID: 32147496. DOI: 10.1016/j.antiviral.2020.104762. PMC: 7132364 [Consulta: 19 abril 2020].
Multicenter collaboration group of Department of Science Technology of Guangdong Province Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia «Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia» (en xinés). Chinese Journal of Tuberculosis and Respiratory Diseases (Zhonghua Jie He He Hu Xi Za Zhi), 43, febrer 2020, pàg. E019. DOI: 10.3760/cma.j.issn.1001-0939.2020.0019. PMID: 32075365.
Self, Wesley H.; Semler, Matthew W.; Leither, Lindsay M.; Casey, Jonathan D.; Angus, Derek C.; Brower, Roy G.; Chang, Steven Y.; Collins, Sean P.; Eppensteiner, John C. «Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19». JAMA, 324, 21, novembre 2020, pàg. 2165–2176. DOI: 10.1001/jama.2020.22240. PMC: 7653542. PMID: 33165621.
Miossec, P «Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation» (en anglès). Eur J Rheumatol, 2020; Maig 11, pàgs: 2. ISSN 2148-4279. DOI: 10.5152/eurjrheum.2020.2062. PMID: 32412405 [Consulta: 18 maig 2020].^{[Enllaç no actiu]}
Touret, F; de Lamballerie, X «Of chloroquine and COVID-19» (en anglès). Antiviral Res, 2020 Maig; 177, pp: 104762. PMID: 32147496. DOI: 10.1016/j.antiviral.2020.104762. PMC: 7132364 [Consulta: 6 setembre 2020].
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D; 8 «In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)». Clinical Infectious Diseases, 2020; Mar 9, pp: ciaa237. DOI: 10.1093/cid/ciaa237. PMC: 7108130. PMID: 32150618.
Mehra, Mandeep R.; Desai, Sapan S.; Ruschitzka, Frank; Patel, Amit N. «Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis» (en anglès). The Lancet (Epub AoP), 22-05-2020. DOI: 10.1016/S0140-6736(20)31180-6. ISSN: 0140-6736. PMID: 32450107.
Mitjà, Oriol; Corbacho-Monné, Marc; Ubals, Maria; Tebe, Cristian; Peñafiel, Judith «Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial». Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 16-07-2020. DOI: 10.1093/cid/ciaa1009. ISSN: 1537-6591. PMC: 7454406. PMID: 32674126.
Andreakos E, Tsiodras S «COVID-19: lambda interferon against viral load and hyperinflammation» (en anglès). EMBO Mol Med, 2020; Maig 25, pp: e12465. ISSN 1757-4684. DOI: 10.15252/emmm.202012465. PMID: 32333818 [Consulta: 9 juny 2020].
Mantlo, E; Bukreyeva, N; Maruyama, J; Paessler, S; Huang, C «Antiviral activities of type I interferons to SARS-CoV-2 infection» (en anglès). Antiviral Res, 2020 Jul; 179, pp: 104811. PMID: 32360182. DOI: 10.1016/j.antiviral.2020.104811. PMC: 7188648 [Consulta: 26 juny 2020].
Selvaraj, V; Kwame Dapaah-Afriyie, K; Finn, A; Flanigan, TP «Short-Term Dexamethasone in Sars-CoV-2 Patients» (en anglès). R I Med J (2013), 2020 Jun 19; 103 (6), pp: 39-43. ISSN 2327-2228. PMID: 32570995 [Consulta: 26 juny 2020].
Yang, JW; Yang, L; Luo, RG; Xu, JF «Successful use of methylprednisolone for treating severe COVID-19» (en anglès). Clin Microbiol Infect, 2020; Maig 29 (Epub Aop), pàgs: 5. PMID: 32479759. DOI: 10.1016/j.jaci.2020.05.021. PMC: 7256545 [Consulta: 3 juliol 2020].
Konig MF, Powell MA, Staedtke V, Bai RY, et al «Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists» (en anglès). J Clin Invest, 2020; Maig 26, pii: 139642. ISSN 1558-8238. DOI: 10.1172/JCI139642. PMID: 32352407 [Consulta: 26 juny 2020].
Rodríguez-Baño, J; Pachón, J; Carratalà, J; Ryan, P; et al «Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)». Clin Microbiol Infect, 2020; Ag 26, pp: S1198-743X(20)30492-4. DOI: 10.1016/j.cmi.2020.08.010. PMC: 7449935. PMID: 32860964 [Consulta: 1r setembre 2020].
Mehta, P; Porter, JC; Manson, JJ; Isaacs, JD; Openshaw, PJM; McInnes, IB; Summers, C; Chambers, RC «Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities». Lancet Respir Med, 16-06-2020, pp: S2213-2600(20)30267-8. DOI: 10.1016/S2213-2600(20)30267-8. ISSN: 2213-2619. PMID: 32559419 [Consulta: 25 juny 2020].
Stallmach, A; Kortgen, A; Gonnert, F; Coldewey, SM; et al «Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series». Crit Care, 2020 Jul 17; 24 (1), pp: 444. DOI: 10.1186/s13054-020-03158-0. ISSN: 1466-609X. PMID: 32680535 [Consulta: 21 juliol 2020].
Cavalli, G; De Luca, G; Campochiaro, C; Della-Torre, E; et al «Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study». Lancet Rheumatol, 2020 Jun; 2 (6), pp: e325-e331. DOI: 10.1016/S2665-9913(20)30127-2. PMC: 7252085. PMID: 32501454 [Consulta: 1r setembre 2020].
Huet, T; Beaussier, H; Voisin, O; Jouveshomme, S; et al «Anakinra for severe forms of COVID-19: a cohort study». Lancet Rheumatol, 2020 Jul; 2 (7), pp: e393-e400. DOI: 10.1016/S2665-9913(20)30164-8. PMC: 7259909. PMID: 32835245 [Consulta: 1r setembre 2020].
Chen, P; Nirula, A; Heller, B; Gottlieb, RL; et al «SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19» (en anglès). , 2020; Oct 28, pàgs: 18. PMID: 33113295. DOI: 10.1056/NEJMoa2029849. ISSN: 1533-4406 [Consulta: 10 novembre 2020].
Casadevall A, Pirofski LA «The convalescent sera option for containing COVID-19». The Journal of Clinical Investigation, 130, 4, 13-03-2020, pp: 1545–1548. DOI: 10.1172/JCI138003. PMC: 7108922. PMID: 32167489.
Piechotta, Vanessa; Chai, Khai Li; Valk, Sarah J.; Doree, Carolyn; Monsef, Ina; Wood, Erica M.; Lamikanra, Abigail; Kimber, Catherine; McQuilten, Zoe; So-Osman, Cynthia; Estcourt, Lise J. «Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review». The Cochrane Database of Systematic Reviews, 7, 10-07-2020, pàg. CD013600. DOI: 10.1002/14651858.CD013600.pub2. ISSN: 1469-493X. PMID: 32648959.
AminJafari, A; Ghasemi, S «The possible of immunotherapy for COVID-19: A systematic review» (en anglès). Int Immunopharmacol, 2020 Jun; 83, pp: 106455. PMID: 32272396. DOI: 10.1016/j.intimp.2020.106455. PMC: 7128194 [Consulta: 15 juliol 2020].
Montelongo-Jauregui, D; Vila, T; Sultan, AS; Jabra-Rizk, MA «Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease» (en anglès). PLoS Pathog, 2020 Ag 12; 16 (8), pp: e1008735. PMID: 32785259. DOI: 10.1371/journal.ppat.1008735. PMC: 7423094 [Consulta: 15 desembre 2020].
Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M «COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19» (en anglès). Antibody Therapeutics, 2020 Ag 19; 3 (3), pp: 204–211. DOI: 10.1093/abt/tbaa020. ISSN: 2516-4236. PMC: 7454247.
Mohapatra, Prasanta Raghab; Mishra, Baijayantimala; Behera, Bijayini «BCG vaccination induced protection from COVID-19» (en anglès). The Indian Journal of Tuberculosis, 07-08-2020, pàgs: 11. ISSN 0019-5707. DOI: 10.1016/j.ijtb.2020.08.004. PMC: 7413058.
Curtis, N; Sparrow, A; Ghebreyesus, TA; Netea, MG «Considering BCG vaccination to reduce the impact of COVID-19» (en anglès). Lancet, 2020 Maig 16; 395 (10236), pp: 1545-1546. DOI: 10.1016/S0140-6736(20)31025-4. PMC: 7252177. PMID: 32359402 [Consulta: 11 novembre 2020].
Noval Rivas, M; Ebinger, JE; Wu, M; Sun, N; et al «BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers» (en anglès). J Clin Invest, 2020; Nov 19, pp: 145157. DOI: 10.1172/JCI145157. ISSN: 1558-8238. PMID: 33211672 [Consulta: 20 desembre 2020].
Takahashi, Harutaka «Role of latent tuberculosis infections in reduced COVID-19 mortality: Evidence from an instrumental variable method analysis» (en anglès). Medical Hypotheses, 144, 04-11-2020, pp: 110214. ISSN 0306-9877. DOI: 10.1016/j.mehy.2020.110214. PMC: 7448767.

nih.gov

(9 novembre 2020). "Hydroxychloroquine does not benefit adults hospitalized with COVID-19". Nota de premsa. Aquest article incorpora text d'aquesta font, la qual és de domini públic.
National Institutes of Health (NIH) «Hydroxychloroquine does not benefit adults hospitalized with COVID-19». News Releases, 09-11-2020 [Consulta: 9 novembre 2020].

pubmed.ncbi.nlm.nih.gov

Cao B, Wang Y, Wen D, Liu W, et al «A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19». The New England Journal of Medicine, 382, 19, 07-05-2020, pp: 1787–1799. DOI: 10.1056/NEJMoa2001282. PMC: 7121492. PMID: 32187464.

ncit.nci.nih.gov

NCI Thesaurus «Lenzilumab» (en anglès). National Cancer Institute, NIH. US Department of Health and Human Services, 2020 Maig 26; C125081 (rev), pàgs: 2 [Consulta: 25 juny 2020].

pubchem.ncbi.nlm.nih.gov

PubChem «Infliximab» (en anglès). NCBI, US National Library of Medicine, 2020 Mar 14; Substance Record SID 178101701 (rev), pàgs: 6 [Consulta: 21 juliol 2020].

nytimes.com

«Citing safety concerns, the W.H.O. paused tests of a drug Trump said he had taken». The New York Times, 26-05-2020.

oup.com

academic.oup.com

Gregoire, M; Le Turnier, P; Gaborit, BJ; Veyrac, G; et al «Lopinavir pharmacokinetics in COVID-19 patients» (en anglès). J Antimicrob Chemother, 2020; Maig 22, pp: dkaa195. ISSN 1460-2091. DOI: 10.1093/jac/dkaa195. PMID: 32443151 [Consulta: 23 maig 2020].
Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M «COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19» (en anglès). Antibody Therapeutics, 2020 Ag 19; 3 (3), pp: 204–211. DOI: 10.1093/abt/tbaa020. ISSN: 2516-4236. PMC: 7454247.

pfizer.com

«Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death». , 14-12-2021.

publico.es

ACN «Un assaig clínic demostra que un antiviral és el primer fàrmac eficaç contra el coronavirus». Públic, 2020, Abr 30, pàgs: 2 [Consulta: 14 maig 2020].

rdif.ru

«Russian Ministry of Health approves the first COVID-19 drug Avifavir produced by JV of RDIF and ChemRar». RDIF, 30-05-2020 [Consulta: 31 maig 2020]. «Còpia arxivada». Arxivat de l'original el 2020-10-06. [Consulta: 29 maig 2022].

recoverytrial.net

Chief Investigators Team. «Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 — RECOVERY Trial». www.recoverytrial.net, 16-06-2020. [Consulta: 17 juny 2020].

reuters.com

Mason, J; Blenkinsop, P «Gilead's COVID-19 antiviral remdesivir gets conditional EU clearance» (en anglès). Reuters, 2020; Juliol 3, págs: [Consulta: 4 juliol 2020].
«Russia plans coronavirus vaccine clinical trials in two weeks». Reuters, 30-05-2020 [Consulta: 31 maig 2020].
Shields, M; Farge, E «WHO set to resume hydroxychloroquine trial in battle against COVID-19» (en anglès). Health News, Reuters, 2020; Juny 3, pàgs: 3 [Consulta: 3 juny 2020].
Liu, Roxanne; Miller, Josh. «China approves use of Roche drug in battle against coronavirus complications». Reuters, 03-03-2020. [Consulta: 14 març 2020].

rimed.org

Selvaraj, V; Kwame Dapaah-Afriyie, K; Finn, A; Flanigan, TP «Short-Term Dexamethasone in Sars-CoV-2 Patients» (en anglès). R I Med J (2013), 2020 Jun 19; 103 (6), pp: 39-43. ISSN 2327-2228. PMID: 32570995 [Consulta: 26 juny 2020].

sciencedirect.com

Caly, L., Druce, J.D., Catton, M.G., Jans, D.A. and Wagstaff, K.M. (2020). The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, [online] p.104787. Available at: https://www.sciencedirect.com/science/article/pii/S0166354220302011# [Accessed 5 Apr. 2020].

sciencemag.org

Kupferschmidt, Kai; Cohen, Jon «WHO launches global megatrial of the four most promising coronavirus treatments». Science Magazine, 22-03-2020. DOI: 10.1126/science.abb8497 [Consulta: 27 març 2020].

scmp.com

«Chinese military scientists ordered to win global race to develop coronavirus vaccine». South China Morning Post, 19-03-2020 [Consulta: 22 març 2020].

statnews.com

Fox, Maggie «Drug makers are racing to develop immune therapies for Covid-19. Will they be ready in time?». Stat, 19-03-2020 [Consulta: 21 març 2020].

technologyreview.com

«Which Covid-19 drugs work best?». MIT Technology Review.

theconversation.com

Seley-Radtke, Katherine «A small trial finds that hydroxychloroquine is not effective for treating coronavirus». The Conversation, 03-04-2020 [Consulta: 28 abril 2020].

theguardian.com

«Japanese flu drug 'clearly effective' in treating coronavirus, says China». , 18-03-2020.
Davey, Melissa; Kirchgaessner, Stephanie; Boseley, Sara «Governments and WHO changed Covid-19 policy based on suspect data from tiny US company». The Guardian, 03-06-2020 [Consulta: 4 juny 2020].

thelancet.com

COVID-19 Clinical Research Coalition «Global coalition to accelerate COVID-19 clinical research in resource-limited settings». Lancet, 395, 10233, abril 2020, pàg. 1322–1325. DOI: 10.1016/s0140-6736(20)30798-4. PMC: 7270833. PMID: 32247324.
Mehra, Mandeep R.; Desai, Sapan S.; Ruschitzka, Frank; Patel, Amit N. «Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis» (en anglès). The Lancet (Epub AoP), 22-05-2020. DOI: 10.1016/S0140-6736(20)31180-6. ISSN: 0140-6736. PMID: 32450107.
Editors «Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis» (en anglès). The Lancet, 2020; Jun 3, pàgs: 1. DOI: 10.1016/S0140-6736(20)31290-3 [Consulta: 4 juny 2020].
Mehta, P; Porter, JC; Manson, JJ; Isaacs, JD; Openshaw, PJM; McInnes, IB; Summers, C; Chambers, RC «Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities». Lancet Respir Med, 16-06-2020, pp: S2213-2600(20)30267-8. DOI: 10.1016/S2213-2600(20)30267-8. ISSN: 2213-2619. PMID: 32559419 [Consulta: 25 juny 2020].

uniprot.org

UniProt «Transmembrane protease serine 2» (en anglès). Protein knowledgebase. UniProt Consortium, 2019 Feb 26; O15393 -TMPS2_HUMAN- (rev), pàgs: 15 [Consulta: 6 abril 2020].

web.archive.org

Milken Institute. «COVID-19 treatment and vaccine tracker», 02-04-2020. Arxivat de l'original el 27 de març 2020. [Consulta: 2 abril 2020].
Beeching, Nicholas J.; Fletcher, Tom E.; Fowler, Robert «BMJ Best Practices: COVID-19». BMJ, 2020; Abr 14 (rev), pàgs: 111. Arxivat de l'original el 19 de desembre 2020 [Consulta: 20 desembre 2020].
«Russian Ministry of Health approves the first COVID-19 drug Avifavir produced by JV of RDIF and ChemRar». RDIF, 30-05-2020 [Consulta: 31 maig 2020]. «Còpia arxivada». Arxivat de l'original el 2020-10-06. [Consulta: 29 maig 2022].

who.int

WHO «WHO Director-General's opening remarks at the media briefing on COVID-19» (en anglès). DG Speeches, 2020; Maig 25, pàgs: 4 [Consulta: 29 abril 2020].

worldcat.org

Maguire, Brittany J.; Guérin, Philippe J. «A living systematic review protocol for COVID-19 clinical trial registrations». Wellcome Open Research, 5, 02-04-2020, pàg. 60. DOI: 10.12688/wellcomeopenres.15821.1. ISSN: 2398-502X. PMC: 7141164. PMID: 32292826.
«Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic». Canadian Medical Association Journal, 192, 15, 26-03-2020, pàg. E405–E407. DOI: 10.1503/cmaj.200438. ISSN: 0820-3946. PMC: 7162442. PMID: 32336678 [Consulta: 27 març 2020].
Shaffer, L «15 drugs being tested to treat COVID-19 and how they would work» (en anglès). Nat Med, 2020; Maig 15, pàgs: 8. ISSN 1546-170X. DOI: 10.1038/d41591-020-00019-9. PMID: 32415251 [Consulta: 19 maig 2020].
Li G, De Clercq E «Therapeutic options for the 2019 novel coronavirus (2019-nCoV)». Nature Reviews. Drug Discovery, 19, 3, març 2020, pàg. 149–150. ISSN 1474-1784. DOI: 10.1038/d41573-020-00016-0. PMID: 32127666.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T; 8 «Compassionate Use of Remdesivir for Patients with Severe Covid-19». N Engl J Med, 2020 Abr; 10, pàgs: 19. ISSN 1533-4406. DOI: 10.1056/NEJMoa2007016. PMID: 32275812.
Gregoire, M; Le Turnier, P; Gaborit, BJ; Veyrac, G; et al «Lopinavir pharmacokinetics in COVID-19 patients» (en anglès). J Antimicrob Chemother, 2020; Maig 22, pp: dkaa195. ISSN 1460-2091. DOI: 10.1093/jac/dkaa195. PMID: 32443151 [Consulta: 23 maig 2020].
Gao J, Tian Z, Yang X «Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies» (en anglès). Bioscience Trends, 14, 1, 19-02-2020, pp: 72–73. DOI: 10.5582/bst.2020.01047. ISSN: 1881-7823. PMID: 32074550.
Miossec, P «Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation» (en anglès). Eur J Rheumatol, 2020; Maig 11, pàgs: 2. ISSN 2148-4279. DOI: 10.5152/eurjrheum.2020.2062. PMID: 32412405 [Consulta: 18 maig 2020].^{[Enllaç no actiu]}
Mehra, Mandeep R.; Desai, Sapan S.; Ruschitzka, Frank; Patel, Amit N. «Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis» (en anglès). The Lancet (Epub AoP), 22-05-2020. DOI: 10.1016/S0140-6736(20)31180-6. ISSN: 0140-6736. PMID: 32450107.
Mitjà, Oriol; Corbacho-Monné, Marc; Ubals, Maria; Tebe, Cristian; Peñafiel, Judith «Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial». Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 16-07-2020. DOI: 10.1093/cid/ciaa1009. ISSN: 1537-6591. PMC: 7454406. PMID: 32674126.
Andreakos E, Tsiodras S «COVID-19: lambda interferon against viral load and hyperinflammation» (en anglès). EMBO Mol Med, 2020; Maig 25, pp: e12465. ISSN 1757-4684. DOI: 10.15252/emmm.202012465. PMID: 32333818 [Consulta: 9 juny 2020].
Selvaraj, V; Kwame Dapaah-Afriyie, K; Finn, A; Flanigan, TP «Short-Term Dexamethasone in Sars-CoV-2 Patients» (en anglès). R I Med J (2013), 2020 Jun 19; 103 (6), pp: 39-43. ISSN 2327-2228. PMID: 32570995 [Consulta: 26 juny 2020].
Konig MF, Powell MA, Staedtke V, Bai RY, et al «Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists» (en anglès). J Clin Invest, 2020; Maig 26, pii: 139642. ISSN 1558-8238. DOI: 10.1172/JCI139642. PMID: 32352407 [Consulta: 26 juny 2020].
Mehta, P; Porter, JC; Manson, JJ; Isaacs, JD; Openshaw, PJM; McInnes, IB; Summers, C; Chambers, RC «Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities». Lancet Respir Med, 16-06-2020, pp: S2213-2600(20)30267-8. DOI: 10.1016/S2213-2600(20)30267-8. ISSN: 2213-2619. PMID: 32559419 [Consulta: 25 juny 2020].
Stallmach, A; Kortgen, A; Gonnert, F; Coldewey, SM; et al «Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series». Crit Care, 2020 Jul 17; 24 (1), pp: 444. DOI: 10.1186/s13054-020-03158-0. ISSN: 1466-609X. PMID: 32680535 [Consulta: 21 juliol 2020].
Chen, P; Nirula, A; Heller, B; Gottlieb, RL; et al «SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19» (en anglès). , 2020; Oct 28, pàgs: 18. PMID: 33113295. DOI: 10.1056/NEJMoa2029849. ISSN: 1533-4406 [Consulta: 10 novembre 2020].
Piechotta, Vanessa; Chai, Khai Li; Valk, Sarah J.; Doree, Carolyn; Monsef, Ina; Wood, Erica M.; Lamikanra, Abigail; Kimber, Catherine; McQuilten, Zoe; So-Osman, Cynthia; Estcourt, Lise J. «Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review». The Cochrane Database of Systematic Reviews, 7, 10-07-2020, pàg. CD013600. DOI: 10.1002/14651858.CD013600.pub2. ISSN: 1469-493X. PMID: 32648959.
Wang, C; Li, W; Drabek, D; Okba, NMA; et al «A human monoclonal antibody blocking SARS-CoV-2 infection» (en anglès). Nature Communications, 2020 Maig 4; 11 (2251), pàgs: 25. ISSN 2041-1723 [Consulta: 5 maig 2020].
Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M «COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19» (en anglès). Antibody Therapeutics, 2020 Ag 19; 3 (3), pp: 204–211. DOI: 10.1093/abt/tbaa020. ISSN: 2516-4236. PMC: 7454247.
Mohapatra, Prasanta Raghab; Mishra, Baijayantimala; Behera, Bijayini «BCG vaccination induced protection from COVID-19» (en anglès). The Indian Journal of Tuberculosis, 07-08-2020, pàgs: 11. ISSN 0019-5707. DOI: 10.1016/j.ijtb.2020.08.004. PMC: 7413058.
Noval Rivas, M; Ebinger, JE; Wu, M; Sun, N; et al «BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers» (en anglès). J Clin Invest, 2020; Nov 19, pp: 145157. DOI: 10.1172/JCI145157. ISSN: 1558-8238. PMID: 33211672 [Consulta: 20 desembre 2020].
Takahashi, Harutaka «Role of latent tuberculosis infections in reduced COVID-19 mortality: Evidence from an instrumental variable method analysis» (en anglès). Medical Hypotheses, 144, 04-11-2020, pp: 110214. ISSN 0306-9877. DOI: 10.1016/j.mehy.2020.110214. PMC: 7448767.